{
    "Question": "Should patients with MTX-na√Øve and non-MTX csDMARDs exposed RA and low disease activity receive csDMARD monotherapy or csDMARD combination (double or triple) therapy?",
    "Comparison": {
        "csDMARD triple combination therapy versus csDMARD monotherapy. Data based on indirect RCT evidence.": {
            "filename": "PICO 3b_Comparison 2.json",
            "Explanations": {
                "a": "Downgraded by one level due to serious indirecteness. The population has moderate disease activity.",
                "b": "csDMARD triple therapy includes MTX + SSZ + HCQ.",
                "c": "csDMARD monotherapy includes MTX.",
                "d": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting harm. Low number of events."
            }
        }
    },
    "References": {
        "1": "Moreland LW, Zhang J. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The treatment of early aggressive rheumatoid arthritis trial. Arthritis and Rheumatism. 2012;64(9):2824."
    }
}